TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: Distinct patterns in never, former, and current smokers

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5076-5083

  Le Calvez, Florence ^a   Mukeria, Anush ^b   Hunt, Jay D ^a,c   Kelm, Olaf ^a   Hung, Rayjean J ^a   Tanière, Philippe ^d   Brennan, Paul ^a   Boffetta, Paolo ^a   Zaridze, David G ^b   Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Cancer Research Center   (Russian Federation)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CYCLOOXYGENASE 2; K RAS PROTEIN; NITRIC OXIDE; PROTEIN P53; TOBACCO SMOKE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CHILD; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; EXON; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RISK FACTOR; SMOKING; SMOKING HABIT; SQUAMOUS CELL CARCINOMA;

AGED; CYCLOOXYGENASE 2; FEMALE; GENES, P53; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SMOKING; TUMOR SUPPRESSOR PROTEIN P53; TYROSINE;

EID: 20444480258     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0551     Document Type: Article

References (53)

1. IARC. IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Tobacco smoke and involuntary smoking. Vol. 83. Lyon (France): IARC. 2004.
2. Dockery DW, Trichopoulos D. Risk of lung cancer from environmental exposures to tobacco smoke. Cancer Causes Control 1997;8:333-45.
3. Boffetta P, Agudo A, Ahrens W, et al. Multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in Europe. J Natl Cancer Inst 1998;90:1440-50.
4. Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull 2003;68:71-94.
5. Jedrychowski W, Becher H, Wahrendorf J, Basa-Cierpialek Z, Gomola K. Effect of tobacco smoking on various histological types of lung cancer. J Cancer Res Clin Oncol 1992;118:276-82.
6. Koo LC, Ho JH. Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol 1990;19 Suppl 1:S14-23.
7. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci 2004;95:197-204.
8. Cooper CA, Carby FA, Bubb VJ, Lamb D, Kerr KM, Wyllie AH. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol 1997;181:401-4.
9. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
10. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52:2665-9S.
11. Husgafvel-Pursiainen K, Boffetta P, Kannio A, et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res 2000;60:2906-11.
12. Husgafvel-Pursiainen K, Hackman P, Ridanpaa M, et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer 1993;53:250-6.
13. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153-60.
14. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366-73.
15. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
16. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002;21:7435-51.
17. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-2.
18. Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000;92:803-11.
19. Hussain SP, Amstad P, Raja K, et al. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res 2001;61:6350-5.
20. Guinee DG Jr, Travis WD, Trivers GE, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 1995;16:993-1002.
21. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003;21:229-39.
22. Mannetje A, Fevotte J, Fletcher T, et al. Assessing exposure misclassification by expert assessment in multicenter occupational studies. Epidemiology 2003;14:585-92.
23. Castelao JE, Bart RD III, DiPerna CA, Sievers EM, Bremner RM. Lung cancer and cyclooxygenase-2. Ann Thorac Surg 2003;76:1327-35.
24. Pignatelli B, Li CQ, Boffetta P, et al. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 2001;61:778-84.
25. Ohshima H, Friesen M, Brouet I, Bartsch H. Nitrotyrosine as a new marker for endogenous nitrosation and nitration of proteins. Food Chem Toxicol 1990;28:647-52.
26. Taniere P, Martel-Planche G, Maurici D, et al. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol 2001;158:33-40.
27. Anker P, Lefort F, Vasioukhin V, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997;112:1114-20.
28. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002;21:7435-51.
29. Paschke T. Analysis of different versions of the IARC p53 database with respect to G- →T transversion mutation frequencies and mutation hotspots in lung cancer of smokers and non-smokers. Mutagenesis 2000;15:457-8.
30. Rodin SN, Rodin AS. Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci U S A 2000;97:12244-9.
31. Rodin SN, Rodin AS. On the origin of p53 G:C - → T:A transversions in lung cancers. Mutat Res 2002;508:1-19.
32. Kondo K, Tsuzuki H, Sasa M, Sumitomo M, Uyama T, Monden Y. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 1996;61:20-6.
33. Chen RH, Maher VM, Brouwer J, van de PP, McCormick JJ. Preferential repair and strand-specific repair of benzoapyrene diol epoxide adducts in the HPRT gene of diploid human fibroblasts. Proc Natl Acad Sci U S A 1992;89:5413-7.
34. Hainaut P, Pfeifer GP. Patterns of p53 G- →T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22:367-74.
35. Yoon JH, Smith LE, Feng Z, Tang M, Lee CS, Pfeifer GP. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers. Cancer Res 2001;61:7110-7.
36. Henderson PT, Delaney JC, Gu F, Tannenbaum SR, Essigmann JM. Oxidation of 7,8-dihydro-8-oxoguanine affords lesions that are potent sources of replication errors in vivo. Biochemistry 2002;41:914-21.
37. Hecht SS. Biochemistry, biology, and carcinogeniciry of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998;11:559-603.
38. Moriya M, Zhang W, Johnson F, Grollman AP. Mutagenic potency of exocyclic DNA adducts: marked differences between Escherichia coli and simian kidney cells. Proc Natl Acad Sci U S A 1994;91:11899-903.
39. 6-ethenodeoxyadenosine, a DNA adduct highly mutagenic in mammalian cells. Biochemistry 1996;35:11487-92.
40. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
41. Campomenosi P, Monti P, Aprile A, et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 2001;20:3573-9.
42. Di Como CJ, Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 1998;16:2527-39.
43. Shiraishi K, Kato S, Han SY, et al. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 2004;279:348-55.
44. Vahakangas KH, Bennett WP, Castren K, et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 2001;61:4350-6.
45. Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 1999;8:297-302.
46. Takagi Y, Osada H, Kuroishi T, et al. p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br J Cancer 1998;77:1568-72.
47. Marchetti A, Pellegrini S, Sozzi G, et al. Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. Br J Cancer 1998;78:73-8.
48. U.S. Environmental Protection Agency. Respiratory health effects of passive smoking: lung cancer and other disorders. Vol. EPA/600/6-90/006F. Washington (DC): U.S. Environmental Protection Agency, 1993; 1993.
49. 6-pyridyloxobutylation by the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Biochemistry 2004;43:540-9.
50. van d V, Eiserich JP, Cross CE. Nitric oxide: a proinflammatory mediator in lung disease? Respir Res 2000;1:67-72.
51. Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med 2000;162:701-6.
52. Di Stefano A, Caramori G, Ricciardolo FL, Capelli A, Adcock IM, Donner CF. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin Exp Allergy 2004;34:1156-67.
53. Ambs S, Bennett WP, Merriam WG, et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999;91:86-8.